Arginox Pharmaceuticals, Inc.

Menlo Park, CA 94025

SBIR Award Summary

Total Number of Awards 3
Total Value of Awards $592K
First Award Date 08/18/03
Most Recent Award Date 09/01/04

Key Personnel

Last Name Name Awards Contact
Lane Paul B Lane 1
Krasnov Peter Krasnov 1
Gross Steven S Gross 1

3 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/04 - 05/31/06

DESCRIPTION (provided by applicant): Hematopoietic cell-supported therapy is employed for a broad spectrum of malignancies and hematological disease. However, the approach is limited by the availability of hematopoietic stem cells; thus, the possibility of expanding the number of hematopoietic stem and progenitor cells is a critical issue for a ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/04 - 06/21/05

DESCRIPTION (provided by applicant): ArgiNOx is a recently-formed Wisconsin-based biotech startup that seeks to develop novel therapies for cardiovascular and inflammatory conditions resulting from insufficient or excess nitric oxide (NO). In the cardiovascular system, NO is an endogenous vasodilator that must be produced at an appropriate level...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/18/03 - 10/31/04

DESCRIPTION (provided by applicant): This is a Fast-track Phase I application from ArgiNOx Inc. to develop a novel pharmacotherapy that may save lives of tens of thousands of patients that develop cardiogenic shock each year in the USA. Cardiogenic shock is lethal in an estimated 60 percent of cases, and occurs in approx. 8 percent of all patien...